Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,609.58
(
1.58%
)
US TECH 100
23,579.20
(
1.27%
)
Dow Jones
46,426.85
(
1.86%
)
Brent Oil
96.58
(
-10.68%
)
Bitcoin
70,976.55
(
4.63%
)
News Focus
News Focus
Post# of 257271
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122808
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 100025

Wednesday, 07/28/2010 3:24:11 PM

Wednesday, July 28, 2010 3:24:11 PM

Post# of 257271

Trade secrets are independent of patent and/or H-W.

If clinical data is considered a protected trade secret, why does Hatch-Waxman have a statutory provision that grants data exclusivity for new molecular entities and new indications? And why does the newly enacted FoB law have a provision that grants data exclusivity?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today